Treataware

Treataware logo Treataware (formerly the AIDS Treatment Project Australia) is a specific and dedicated treatment program, auspiced by NAPWA, that aims to promote health monitoring, treatments and treatments awareness, and support education and information initiatives for people living with HIV/AIDS.

The ATPA was formed in 1998 as an extension of the work of the Treatments Working Group of PLWHA NSW, and was subsequently moved under the auspices of NAPWA due to the need for a national outreach program for HIV treatments. in 2008 the project was renamed Treataware.

Treataware's work today includes:

Minimising the risk of cardiovascular disease (updated)

This Treataware fact sheet explains the current knowledge about cardiovascular (heart) disease risk in people living with HIV/AIDS, and some strategies for minimising risk.

Lipoatrophy: options for preventing, managing and treating fat loss associated with HIV treatments (updated)

A Treataware fact sheet on Lipoatrophy – the loss or ‘wasting’ of fat from the face, as well as sometimes the buttocks, upper arms legs or thighs. Options for prevention, treatment and management of fat loss associated with HIV treatments.

Factors to discuss with your doctor when considering your choice of Antiretroviral Drugs

This Treataware fact sheet is a quick reference to the factors people with HIV and their doctors need to consider when choosing an antiretroviral treatment regimen.

Up, up and away: tips for the positive traveller

p(standfirst).  A guide for HIV-positive people who travel overseas, produced by PLWHA NSW in partnership with ACON and Roche and distributed by the AIDS Treatment Project Australia.

Neurological and psychological complications of HIV

This Treataware fact sheet looks at the various neurological and psychological illnesses that affect people with HIV/AIDS including AIDS dementia complex, toxoplasmosis, PML, lymphoma and depression.

HIV and HCV (hepatitis C virus) co-infection

This Treataware fact sheet explains the issues around coinfection with hepatitis C for people with HIV/AIDS, including ways to minimise risk and treatment options.